Kornimate/medical-research-clean huggingface dataset:
prognostic value of anti-ro52 antibodies in connective tissue diseases (a-ro52)

Conditions: Connective Tissue Diseases

Summary: anti-ro52 autoantibodies can be detected in patients with several autoimmune diseases. clinical significance of anti-ro52 is controversial. the presence of anti-ro52 may be a factor associated with disease severity (interstitial lung disease, vasculopathy) and cancers. the aim of this study is to assess interstitial lung disease and vasculopathy prevalence and severity, cancers occurence and others clinical features of connective tissue disease patients with anti-ro52 autoantibodies.


Eligibility criteria:
inclusion criteria: * connective tissue disease (differenciated or not) * presence of anti-ro52 antibodies at diagnosis exclusion criteria: * healthy subjects
medical mindfulness: virtual reality mindfulness therapy for anxiety and pain management in patients with acute and chronic pain

Conditions: Acute Pain; Chronic Pain

Summary: adults and children undergoing medical care (inpatient or outpatient) often experience pain and anxiety either as a result of their medical condition or a side effect of medical procedures. the purpose of this study is to create a registry of patients using virtual reality (vr) mindfulness therapy through different aspects of their medical care to determine if vr mindfulness therapy is more effective than the standard of care (i.e., no technology based distraction) for treating or preventing anxiety and pain in adults and children suffering from chronic pain, gi conditions where pain is a common symptom, or undergoing any painful medical procedure (i.e. iv access, blood draws, endoscopy, surgery). the anticipated primary outcome will be reduction of pain and anxiety for both acute and chronic pain.

inpatient: inpatients will be presented with an informed consent. if they sign the consent, they will then be given a vr headset pre- programmed with content that they may use for the duration of their stay. gi patients headsets will be collected when they are discharged. there are pain and anxiety analog scales at the end of each program. this data will be downloaded to stanford. patient's will not be entering their phi. we will know who has headsets, as they will be numbered. patient who are hospitalized for chronic pain will be allowed to take the vr headset home for month and be asked to return it at their followup outpatient visit. outpatient: patient's who are about to undergo gastrointestinal disease testing or be seen for an outpatient gi appointment will be presented with an informed consent. if they sign the consent, they will be given the vr headset to use prior to their procedure. there are pain and anxiety analog scales at the end of each program. this data will be downloaded to stanford medicine box.patient's will not be entering their phi. we will know who has headsets, as they will be numbered.

Eligibility criteria:
identify inclusion criteria. participants must: 1. be between ages of 5-80 years of age 2. have comprehension of instructions in the english language 3. english speaking 4. must be able to comprehend icf 5. have a medical appointment or procedure at stanford/lpch (inpatient or outpatient) that may cause pain or anxiety. identify exclusion criteria. general exclusion criteria are as follows: 1. significant cognitive impairment/developmental delays 2. seizure disorder 3. history of motion sickness with virtual reality 4. severe visual impairment
fulvestrant in premenopausal women with hormone receptor-positive breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to test the effectiveness and safety of fulvestrant in premenopausal women with advanced breast cancer.

patients will receive an injection of fulvestrant on first day of treatment and then again 2 weeks later and again 2 weeks after that. then patients will receive injections every 4 weeks. routine blood tests will be performed each time an injection is given. patients will be required to complete a hot flash diary, recording the number and severity of hot flashes they experience on a daily basis. after every 12 weeks of treatment, patients' disease will be assessed by x-rays or scans. if there is no disease progression, the patient will continue to receive injections every 4 weeks with reassessment every 8 weeks. patients will continue to receive treatment as long as there is no disease progression or serious side effects.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed invasive breast cancer, with stage iv disease. * tumors must be positive for estrogen receptors, progesterone receptors, or both. * patients must be premenopausal. * prior anti-estrogen therapy (with or without ovarian suppression) * platelet count \> 100,000/mm3 * age older than 18 years * ecog performance status 0-2 exclusion criteria: * hormonal treatment for metastatic disease * pregnant or breast-feeding women * postmenopausal * concurrent hormonal therapy or chemotherapy * prior fulvestrant therapy * more than three prior chemotherapy regimens for metastatic disease * concurrent, long-term anticoagulation therapy * severe, uncontrolled intercurrent illness * history of hypersensitivity to castor oil

Keywords: fulvestrant advanced breast cancer invasive breast cancer stage iv breast cancer hormone receptor-positive breast cancer
clinical validation and safety of the ac 12l ecg system against a standard of care 12-lead ecg (ac 12l ecg)

Conditions: Arrhythmia

Summary: alivecor (www.alivecor.com) has developed an ecg device (kardiamobile) that interfaces with ios and android smartphones and tablets. this ecg consists of a lightweight hardware case with two metal electrodes that can snap onto the back of the phone and a software application. by holding the right finger(s) on the right electrode and the left finger(s) on the left electrode, an electrical circuit is completed and a lead-i, 30 second rhythm strip is created. kardiamobile and a newer device, kardiamobile 6l, were approved by fda for ecg rhythm recording. recently, alivecor developed a new device: kardia 12l to record 12-lead ecgs. however, the data generated from the new device has not yet been validated for accuracy. the specific aim of this study is to evaluate the accuracy and safety of the ac 12l ecg system. the ecgs collected by the ac 12l ecg system will be compared to simultaneous standard- of-care 12-lead ecg, recorded using the ge cardiosoft 12-lead ecg system. the ecgs will be analyzed for accuracy based on statistical difference using root-mean-square error, and cross correlation between the simultaneous 10 second recordings as well as the median beats of all 12 leads.


Eligibility criteria:
inclusion criteria: * male or female patients 18 years or older * ability to remain supine for a conventional 12 lead alivecor 12l ecg recording for approximately 15 minutes exclusion criteria: * open chest wounds or recent (\<30 days) surgery to the chest or abdomen * absence of any limb that would require modification of the lead set-up
umbilical cord derived mesenchymal stem cells therapy in systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: this study is to evaluate the safety and efficacy of human umbilical cord derived mesenchymal stem cells transplantation in systemic lupus erythematosus.

to ensure that all patients of systemic lupus erythematosus (sle) completed 6-months follow-up, twenty sle patients ranging from 14 to 60 years old were enrolled in this trial. participants matched with the inclusion criteria were allocated randomly into two groups:human umbilical cord derived mesenchymal stem cells (huc-mscs) treated group and control group. clinical trials are being increasingly established to investigate the therapeutic potential of these cells for sle. the aim of the present study is to investigate safety and efficacy of vein infusion of allogeneic huc-mscs in patients with sle.

Eligibility criteria:
inclusion criteria: 1. diagnosis of sle(systemic lupus erythematosus) from american college of rheumatology(acr) according to established criteria in 1997 2. age from 14 to 60 years 3. no serious infection or acute hemorrhage 4. left ventricular ejection fraction (lvef)≥ 50% 5. both transaminase and serum creatinine level are more than twice times the upper limit of normal 6. no acute infectious diseases. 7. understanding and willingness to sign a written informed consent document. exclusion criteria: patients with sle have to be disqualified from this study if any of the following is applicable: 1. sle(systemic lupus erythematosus) with severe infection. 2. severe heart attack, liver and kidney disease following serious complications 3. patients with allergic constitution. 4. pregnancy and breastfeeding women. 5. accompanied by malignant tumors or other malignant disease 6. patients as participant in the other clinical text 7. patients with active tuberculosis, acute sever hepatitis or infectious period of diseases.
retrospective foot and ankle data collection

Conditions: Lower Limb Surgery

Summary: a retrospective post-market data collection study of the following implant devices : * darco™ headed cannulated screw * ortholoc™ 3di recon-midfoot/flatfoot system * ortholoctm 3di 2 foot reconstruction system: crosscheck™ module

a retrospective post-market data collection study designed to collect safety and performance standard of care data on patients who have undergone routine lower limb surgery that involved one of the following implant devices as per the indication for use: * darco™ headed cannulated screw * ortholoc™ 3di recon-midfoot/flatfoot system * ortholoctm 3di 2 foot reconstruction system: crosscheck™ module

Eligibility criteria:
inclusion criteria: patients 18 years or older at the time of index procedure • patients who previously received: * the charlotte™ muc screw system in accordance with the indications for use: for fixation of bone fractures or for bone reconstruction. * the crosschecktm in accordance with the indications for use: stabilization of fresh fractures, revision procedures, joint fusion and reconstruction of small bones of the feet. * the ortholoc™ 3di recon-midfoot/flatfoot system in accordance with the indications for use: stabilization of fresh fractures, revision procedures, joint fusion and reconstruction of small bones of the feet. * a darco™ headed cannulated screw in accordance with the indications for use: for bone fracture fixation and bone fragment fixation. exclusion criteria: * none
comparison of one-port and two-port tissue expanders for breast reconstruction

Conditions: Breast Cancer

Summary: appropriate patients undergoing going immediate breast reconstruction with tissue expanders following mastectomy will be randomized to receive one-port or two-ports tissue expanders. their clinical course, complications, and outcome will be analyzed.

the goal of this study is to compare a traditional single port expander with a two-port expander for equivalency when used for breast reconstruction following mastectomy. complication rates that will be tracked include seroma, mastectomy skin flap necrosis, infection, wound dehiscence, need for explantation of the expander. management of seromas will be compared between the two groups. the investigators hypothesize that the allox2 expander will be as effective in achieving the final outcome of completion of the second stage of reconstruction with equal or improved complication rates. study design a prospective 1:1 randomized, single center, open label study will compare the traditional 1- port tissue expander with the allox2 2-port expander placed during immediate tissue expander breast reconstruction. due to the nature of the surgery, the study cannot be blinded. patients will be followed until completion of expansion and exchange for the permanent implant which typically takes 2 to 3 months. risks factors that have been previously identified to be associated with increased postoperative complications include smoking, obesity, breast size, diabetes, radiation therapy, and expander fill volume will be identified. the final outcome is completion of expansion and exchange to permanent implant. standard operative procedure and postoperative care will be done. both groups will have the same two external drains placed which is standard operative procedure. complications will be noted at each postoperative clinic visit and entered into a database. complication rates will be compared between the two groups and associations with risk factors will be analyzed. there will be no cross-over into the other group in case of reconstructive failure. treatment failures will be treated in the same fashion in the two groups.

Eligibility criteria:
inclusion criteria: * patient agrees to immediate tissue expander breast reconstruction * a suitable patient for tissue expander reconstruction exclusion criteria: * not a surgical candidate for immediate breast reconstruction * age less than 18 * patient declines tissue expander reconstruction * patient anticipated to need radiation therapy postoperatively
the use of nirs in brachial plexus block

Conditions: Arterio-venous Fistula

Summary: the study is planed on asa i-iii, 18-80 years old 60 patients developing chronic renal failure and needing arteriovenous fistula surgery for dialysis program in istanbul medeniyet university goztepe research hospital. informed consent of the patients will be obtained before surgery.patients with hemoglobinopathy, coagulopathy, wound or infection in the thenar eminence, wound and infection in the supraclavicular region on the side of the regional block, allergic to local anesthetic drugs and mental retardation will not be included in the study. standart monitorization (ecg, peripheral oxygen saturation and non-invasive arterial pressure monitoring) will be made. base and 5 minutes interval values will be recorded until the end of the surgery. the pads of the nirs monitor will be placed on the thenar eminence of both hands and fixed with the help of a draipe and basal measurements will be taken and recorded. the patients will then be divided into two groups according to computer-generated table of random numbers. group l patients will undergo surgical cleansing and sterile draping and infiltrate %5 bupivacaine 15ml. group b the supraclavicular areas of the patients who will undergo surgical procedures will be sterile covered after appropriate sterilization. after the brachial plexus is visualized around the subclavian artery in the supraclavicular region with the help of samsung ultrasound device, bupivacaine 5% 20ml and lidocaine 2% 10ml will be applied around the brachial plexus using a 50mm stimuplex needle. the effectiveness of the block will be evaluated by a single investigator after withdrawal of the needle, either by effective anesthesia with the block or every 10 minutes up to 30 minutes. the sensory block will be evaluated with a 3 point scale and the motor block will be evaluated routinely before and after the modified bromage scale (scored between 0 and 4). after withdrawal of the treated needle, we will contact the relevant nerve dermatome with cold application (cold sf) and ask the patient to classify the degree of cold feeling from 0 to 3. block will be considered unsuccessful if surgical block cannot be provided after 30 minutes or if the patient experiences pain at any time during the operation. the duration of anesthesia occurring after local infiltration of group l and the sensory and motor blockade after group b stimulation is taken will be recorded. in both groups, nirs values will be recorded at 5 minute intervals until the end of the case after local anesthetic application. investigator will call the patients for primer patency of fistula one month after operation.


Eligibility criteria:
inclusion criteria: * asa i-iii, * chronic renal failure and needing arteriovenous fistula surgery exclusion criteria: * hemoglobinopathy * coagulopathy, * wound or infection in the thenar eminence * wound and infection in the supraclavicular region on the side of the regional block * allergic to local anesthetic drugs * mental retardation
post-operative sore throat and gum chewing

Conditions: Anesthesia; Surgery

Summary: the purpose of this study is to determine if chewing gum immediately prior to transport to the operating room reduces the severity of post-operative sore throat in patients who have an lma (laryngeal mask airway) placed for procedures with duration greater than 1 hour.

patients will be randomized into two groups. group 1 will receive a piece of gum immediately prior to transport to the operating room. they will be asked to chew the gum for 2 minutes and then spit the gum in the garbage. group 2 will not receive any gum. they will be asked to swallow twice and have no other intervention.

Eligibility criteria:
inclusion criteria: * outpatient ambulatory surgery * general anesthesia utilizing a laryngeal mask airway * greater than 1 hour duration exclusion criteria: * chronic laryngitis * chronic bronchitis * asthma * gastroesophageal reflux disease * smoking within the last week * non-english speaking
effect of exercises on diaphragmatic excursion in postmenopausal kyphotic women

Conditions: Kyphosis Postural Thoracic

Summary: the present study examined the effect of different types of exercises for improving the age-related hyperkyphotic curve of postmenopausal women and also examined how it affects diaphragmatic excursion and respiratory function. increasing the respiratory functions for elderly will act as a preventive method against nowadays chest diseases.

the study was conducted to examine the effect of exercises on diaphragmatic excursion in postmenopausal kyphotic women. design of study: a prospective, randomized, single-blind, pre-post-test, controlled trial. the study followed the guidelines of declaration of helsinki on the conduct of human research. ethical approval was obtained from the institutional review board at faculty of physical therapy, cairo university before study commencement (no.p.t,rec/012/003800). this study was carried on forty postmenopausal women clinically diagnosed with thoracic kyphosis. they selected randomly from the outpatient clinic of el kaser el-einy university hospital, cairo university. their ages ranged from 50-60 years. randomization of sample selection was achieved using closed envelop way. classification of the sample by simple random way into two groups equal in number, twenty for each group by using forty closed envelop, each twenty envelop contained a name of a group from the two groups (group a) or (group b) and asking each woman to choose one envelop from them, each woman attended to the group according the name of the group written in her envelop.

Eligibility criteria:
inclusion criteria: 1. all postmenopausal women suffering from thoracic kyphosis. 2. their thoracic kyphosis (cobb's) angles were more than 45 degrees. 3. their age ranged from 50-60 years old. 4. their bmi were \>25 and \<30 kg/m2. exclusion criteria: 1. all patients with comorbidities such as cardiac disease and chest diseases as pulmonary fibrosis. 2. patients with previous trauma to the spine, pelvis and lower limbs. 3. patients with a previous history of spinal surgery (such as spinal fusion surgery, vertebroplasty, or kyphoplasty). 4. patients with congenital spinal deformities and scoliosis. 5. patients with a history of spinal tumors, ankylosing spondylitis, osteoporosis and other spondyloarthritis. 6. the patients received medications that might affect the neuromuscular functions at least three months before or during the study course. 7. patients suffered from mental or psychological disorders. 8. patients suffered from inflammatory diseases such as rheumatoid arthritis or polymyalgia rheumatic.

Keywords: postmenopausal kyphosis flexicurve ruler diaphragmatic excursion corrective exercises resisted diaphragmatic breathing
the association between the use of complementary and alternative medicine and medication adherence in hypertensive african-americans

Conditions: Hypertension

Summary: the objective of this study is to better understand strategies used by african americans with hypertension in order to control their blood pressure.

the objective of this study is to better understand strategies used by african americans with hypertension in order to control their blood pressure. through the use of qualitative interviews, the beliefs and attitudes toward complementary medicine of african americans with hypertension will be elucidated.

Eligibility criteria:
inclusion criteria: 1. patients will be african-american adults 18 years or older who were diagnosed with poorly controlled hypertension as defined by the 6th joint national committee guidelines (systolic \>140 and diastolic \>90). 2. patients will also be eligible if they are taking any prescribed anti-hypertensive medications. 3. patients must be able to provide informed consent in english. participants will be recruited from cornell internal medicine associates, the primary care and general medicine practice at cornell medical center, the same site as the parent grant. exclusion criteria: 1. patients who refused to participate. 2. patients who are unable to provide informed consent.

Keywords: african-american hypertension complementary medicine medication adherence
effect of the mobiushd® in patients with heart failure

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: this is a prospective, multi-center, open-label clinical trial intended to evaluate the safety and effectiveness of the mobiushd® in patients with heart failure and reduced ejection fraction.

subjects presenting with class ii, iii or ambulatory iv heart failure with a left ventricular ejection fraction of ≤ 40% and nt-probnp ≥ 400 will be considered for the study. subjects who meet the initial screening requirements will undergo non-invasive imaging of the carotid anatomy to assess adequacy of the anatomy to allow placement of the mobiushd device. eligible subjects will receive an implant placed in the internal carotid artery. following implantation of the device, subjects will be seen at 1 week, 1, 3, 6, 12, 18, and 24 months.

Eligibility criteria:
inclusion criteria: 1. age 18 years or above 2. currently nyha class ii, iii or ambulatory iv heart failure 3. left ventricular ejection fraction ≤ 40% 4. nt-probnp ≥ 400 5. prescribed optimally-tolerated, stable, guideline directed medical therapy (gdmt) per country specific guidelines for the treatment of heart failure for at least 4 weeks 6. six-minute hall walk (6mhw) distance of ≥ 150 m and ≤ 400 m 7. deemed an acceptable candidate for the implant procedure by the investigator exclusion criteria: 1. known or clinically suspected baroreflex failure or autonomic neuropathy 2. currently implanted with a barostimulator device 3. received cardiac resynchronization therapy (crt) within six months of implantation 4. received a cardiomems device within three months of the screening visit 5. history of any prior stroke with permanent neurologic defect or any prior intracranial bleed or other serious brain injury 6. body mass index \> 45 7. serum estimated glomerular filtration rate (egfr) \< 30 ml/min/1.73 m2 8. presence of atherosclerotic plaque in the intended side for implantation as determined by carotid duplex 9. internal ica lumen diameters \ 11.75 mm within the planned location of the implant placement, or evidence of landing zone restrictions, such as inadequate length, vessel tapering, and/or vessel curvature that would preclude safe placement of the implant

Keywords: heart failure mobius hd